Technology Platform

Technology platform

Botulinum neurotoxin domains as tools for engineering novel molecules

 

Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial botulinum neurotoxins

 

Patient Focus

Patient focus

New medicines for debilitating and life threatening diseases

 

Syntaxin is a leader in botulinum toxin biology and applies its expertise to the identification of new therapeutic opportunities

 

Our Partners

Allergan

Syntaxin has an alliance with Allergan, Inc. the manufacturer of BOTOX® (onabotulinumtoxinA) and a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans.

Ipsen Logo Clear 177 x 54 June 2012

Syntaxin has two global alliances with Ipsen to explore the discovery and development of new therapeutic compounds utilising the natural diversity of botulinum neurotoxins.

Latest News

08 May 2013

Syntaxin Hosting Biological Safety: Management and Practice Open Training Course, 13-14 June 2013

Syntaxin Hosting Biological Safety: Management and Practice Open Train...

29 March 2012

Melanie Lee, CEO of Syntaxin, joins the Board of Lundbeck

Oxford (UK), 29 March 2012 - Syntaxin, a biotechnology company special...

Conferences

LSP Biocapital

BioTrinity 2013 14-16 May 2013. Newbury, UK